NEW YORK, May 11, 2026, 5:02 PM EDT
- Shares of Philip Morris jumped over 6% Monday after investors took fresh FDA guidance as a positive sign for the company’s nicotine pouch rollout prospects.
- This shift is notable. ZYN, the nicotine pouch line from PMI, took a hit earlier—U.S. shipments dropped in the first quarter.
- The FDA guidance stops short of granting full approval. Instead, it outlines situations where the agency won’t prioritize enforcement.
Shares of Philip Morris International Inc. surged Monday after U.S. regulators eased immediate enforcement threats targeting certain nicotine pouches and e-cigarettes, handing investors new confidence in the Marlboro maker’s drive toward smoke-free products.
Philip Morris shares climbed 6.5% to $182.11, just off an intraday peak of $182.26. The move outpaced gains in Altria Group and British American Tobacco’s U.S. shares, which saw smaller upticks.
Philip Morris finds itself in a tricky spot. ZYN nicotine pouches gave the company a narrative beyond cigarettes, but first-quarter U.S. ZYN shipments dropped 23.5%. Regulatory holdups have also stalled the launch of new variants like ZYN Ultra, putting expansion plans in limbo.
The Food and Drug Administration on May 8 said it won’t be prioritizing enforcement against some nicotine pouch and e-cigarette products that don’t yet have final marketing authorization—provided they’ve filed a premarket tobacco application and the application is still under review. Companies use the PMTA process to seek FDA permission before rolling out new tobacco products in the U.S.
Goldman Sachs is sticking with its Buy rating on Philip Morris, naming it a top stock idea following the latest guidance, according to Investing.com. The firm noted the policy may let ZYN Ultra hit store shelves within months. Investing.com didn’t mention which Goldman analysts made the call.
Philip Morris had already flagged to investors that ZYN innovations were on the way for the U.S. market—even as ZYN Ultra still faced ongoing FDA review. Back in April, the company reported its smoke-free business accounted for 43% of net revenue in the first quarter. Net revenues climbed 9.1% to $10.1 billion, with adjusted diluted EPS up 16% to $1.96.
Chief Executive Jacek Olczak said, “Our performance exceeded our expectations in the first quarter,” as the company posted results. He singled out IQOS, Philip Morris’s heated-tobacco system, calling it the key force behind the quarter’s numbers. Philip Morris International
There’s a caveat. FDA guidance isn’t legally binding, and the agency emphasized the policy “in no way” signals a product’s odds of full premarket authorization. Officials added they can still target products featuring youth-oriented design, elevated nicotine levels, or other safety red flags. U.S. Food and Drug Administration
The threat isn’t hypothetical—competition is moving fast. British American Tobacco’s Velo keeps turning up the heat on ZYN in the oral nicotine space. Jefferies analyst Andrei Andon-Ionita flagged last month that ZYN volumes are feeling the squeeze, with “continued momentum loss” now on the radar. Velo stands to gain, he said. Reuters
Philip Morris still has to rely on smoke-free products to counteract falling cigarette sales. At last week’s annual meeting, the company reported 2025 net revenues above $40 billion, with smoke-free products contributing nearly $17 billion. CEO Olczak pointed to the first quarter, saying it gave “further confidence” in the company’s growth outlook for 2026. Philip Morris International
At the meeting, shareholders left little doubt. Every one of the 10 director nominees secured a seat, according to an SEC filing. Executive pay passed on an advisory vote, while the push for the company to cover cigarette-filter cleanup costs failed.
Everything hinges on how fast ZYN Ultra actually hits stores—and whether people buy it. Should sales ramp up soon, Monday’s jump might end up being just the start for Philip Morris’s U.S. pouch segment. But if the FDA process drags or competitors keep nibbling away at share, we might be looking at nothing more than a fleeting regulatory pop, not a real shift in the stock’s trajectory.
